Nascent Biotech Inc

Funding phase 2 clinical trials for glioblastoma brain cancer drug

Facebook Twitter LinkedIn

Nascent Biotech is a fully reporting biotech company nearing the completion of phase 1 clinical trials for the treatment of Glioblastoma brain cancer. Phase 1 is anticipated to be completed by the end of Q3 of this year.  Based on the indication from the phase 1 trial, we will immediately file our data with the FDA to gain approval to start phase 2.  The total funding required for a phase 2 study is budgeted to be $15-$18 million. Funding may be phased over the term of the trial with an initial amount of $5 million being raised.  If interest is indicated we can share our data upon a non-disclosure being signed. Company filings may be viewed at www.sec.gov  

Ready to Ask For Funding for your company?

Post a Funding Request